FHL1 blocking peptide

FHL1 Blocking Peptide

Cat. Num. AAA9622185

• Gene Names: FHL1; KYOT; SLIM; FHL-1; FHL1A; FHL1B; FLH1A; SLIM1; XMPMA; SLIM-1; SLIMMER
• Applications: Blocking/Control
• Purity: The purity is >90%,tested by HPLC and MS.
• Synonyms: FHL1; FHL1 Blocking Peptide; bA535K18.1; FHL 1; FHL 1B; FHL-1; FHL1 protein; FHL1_HUMAN; FHL1A; FHL1B; FLH1A; Four and a half LIM domains 1; Four and a half LIM domains protein 1; Four and a half Lin11 Isl 1 and Mec 3 domains 1; four-and-a-half Lin11; Isl-1 and Mec-3; KYO T; KYOT; mouse; homolog of; LIM protein SLIMMER; MGC111107; RAM14-1; RBMX1A; RBMX1B; RBP associated molecule 14-1; RP11-535K18.1; Skeletal muscle LIM protein 1; Skeletal muscle LIM-protein 1; SLIM 1; SLIM; SLIM-1; SLIM1; SLIMMER; XMPMA; FHL1 blocking peptide

• Purity/Purification: The purity is >90%,tested by HPLC and MS.
• Form/Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.

• Applicable Applications for FHL1 blocking peptide: Blocking/Control
• Notes: For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Related Product Information for FHL1 blocking peptide

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

NCBI and Uniprot Product Information

• NCBI GI #: 228480205
• NCBI GeneID: 2273
• NCBI Accession #: NP_001153171.1
• NCBI GenBank Nucleotide #: NP_001153171.1
• UniProt Accession #: Q13642; O95212; Q13230; Q13645; Q5JXI7; Q5M7Y6; Q6IB30; Q9NZ40; Q9UKZ8; Q9Y630; B7Z5T4; B7Z793
• Molecular Weight: 33,579 Da
• NCBI Official Full Name: four and a half LIM domains protein 1 isoform 5
• NCBI Official Synonym Full Names: four and a half LIM domains 1
• NCBI Official Symbol: FHL1
• NCBI Official Synonym Symbols: KYOT; SLIM; FHL-1; FHL1A; FHL1B; FLH1A; SLIM1; XMPMA; SLIM-1; SLIMMER
• NCBI Protein Information: four and a half LIM domains protein 1; LIM protein SLIMMER; four-and-a-half Lin11, Isl-1 and Mec-3 domains 1; skeletal muscle LIM-protein 1
• UniProt Protein Name: Four and a half LIM domains protein 1
• Protein Family: Fork head transcription factor
• UniProt Gene Name: FHL1
• UniProt Synonym Gene Names: SLIM1; FHL-1; SLIM; SLIM-1
• UniProt Entry Name: FHL1_HUMAN

NCBI Description

This gene encodes a member of the four-and-a-half-LIM-only protein family. Family members contain two highly conserved, tandemly arranged, zinc finger domains with four highly conserved cysteines binding a zinc atom in each zinc finger. Expression of these family members occurs in a cell- and tissue-specific mode and these proteins are involved in many cellular processes. Mutations in this gene have been found in patients with Emery-Dreifuss muscular dystrophy. Multiple alternately spliced transcript variants which encode different protein isoforms have been described.[provided by RefSeq, Nov 2009]

Uniprot Description

FHL1 iso1: May have an involvement in muscle development or hypertrophy. Defects in FHL1 are the cause of X-linked dominant scapuloperoneal myopathy (SPM). Scapuloperoneal syndrome (SPS) was initially described more than 120 years ago by Jules Broussard as 'une forme hereditaire d'atrophie musculaire progressive' beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. The etiology of this condition remains unclear. Defects in FHL1 are the cause of X-linked myopathy with postural muscle atrophy (XMPMA). Myopathies are inherited muscle disorders characterized by weakness and atrophy of voluntary skeletal muscle, and several types of myopathy also show involvement of cardiac muscle. XMPMA is a distinct form of adult-onset X-linked recessive myopathy with several features in common with other myopathies, but the presentation of a pseudoathletic phenotype, scapuloperoneal weakness, and bent spine is unique and might render the clinical phenotype distinguishable from other myopathies. Defects in FHL1 are the cause of X-linked severe early- onset reducing body myopathy (RBM). RBM is a rare muscle disorder causing progressive muscular weakness and characteristic intracytoplasmic inclusions in myofibers. Clinical presentations of RBM have ranged from early onset fatal to childhood onset to adult onset cases. Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (CO-RBM). This disorder is allelic to severe early-onset reducing body myopathy (RBM). 5 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell development/differentiation

Chromosomal Location of Human Ortholog: Xq26

Cellular Component: focal adhesion; cytoplasm; plasma membrane; nucleus; cytosol

Molecular Function: protein binding; zinc ion binding

Biological Process: muscle development; organ morphogenesis; positive regulation of potassium ion transport; negative regulation of cell growth; cell differentiation

Disease: Myopathy, Reducing Body, X-linked, Early-onset, Severe; Myopathy, X-linked, With Postural Muscle Atrophy; Myopathy, Reducing Body, X-linked, Childhood-onset; Scapuloperoneal Myopathy, X-linked Dominant